Brokers Set Expectations for AVITA Medical FY2025 Earnings

AVITA Medical, Inc. (NASDAQ:RCEL) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for AVITA Medical in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($1.14) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $21.00 price objective on the stock. The consensus estimate for AVITA Medical’s current full-year earnings is ($2.35) per share.

AVITA Medical (NASDAQ:RCEL) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.21). The firm had revenue of $19.55 million during the quarter, compared to analyst estimates of $19.65 million. AVITA Medical had a negative net margin of 95.47% and a negative return on equity of 194.69%. During the same quarter last year, the firm earned ($0.34) earnings per share.

Several other equities analysts also recently issued reports on the company. Lake Street Capital cut their price objective on AVITA Medical from $20.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of AVITA Medical in a research note on Wednesday, January 8th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $12.00 price target (up previously from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

AVITA Medical Stock Down 2.9 %

Shares of RCEL opened at $8.48 on Wednesday. The company has a market capitalization of $222.35 million, a P/E ratio of -3.80 and a beta of 1.58. AVITA Medical has a one year low of $7.51 and a one year high of $18.93. The business’s 50 day simple moving average is $11.94 and its 200-day simple moving average is $10.65. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.73 and a quick ratio of 3.37.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Essex Investment Management Co. LLC acquired a new position in AVITA Medical in the third quarter valued at about $2,477,000. Barclays PLC increased its stake in shares of AVITA Medical by 340.0% in the 3rd quarter. Barclays PLC now owns 37,503 shares of the company’s stock valued at $402,000 after acquiring an additional 28,979 shares during the last quarter. Jane Street Group LLC raised its position in shares of AVITA Medical by 32.7% in the 3rd quarter. Jane Street Group LLC now owns 89,395 shares of the company’s stock valued at $958,000 after acquiring an additional 22,032 shares during the period. SG Americas Securities LLC acquired a new stake in shares of AVITA Medical in the 4th quarter valued at approximately $190,000. Finally, State Street Corp boosted its stake in AVITA Medical by 2.4% during the 3rd quarter. State Street Corp now owns 519,997 shares of the company’s stock worth $5,574,000 after acquiring an additional 11,997 shares during the last quarter. 27.66% of the stock is currently owned by institutional investors.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.